Maravai LifeSciences HoldingsMRVI
Recorded

Maravai LifeSciences Holdings Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Matt StantonEquity Research Analyst

All right. Great. I think we'll get started. My name's- James. Matt Stanton.

Matt StantonEquity Research Analyst

I'm on the life science tools diagnostics team here at Jefferies. Happy to have Maravai back with us at the conference again this year. I'm going to hand it over to Raj for some opening comments, and then we'll kick it back over here for some Q&A. With that, over to you.

Raj AsarpotaCFO

Matt, thank you for having us and hosting us. I'll be making forward-looking statements today, so keeping that in mind. Like Matt said, a quick overview on the company. Maravai LifeSciences is a leading provider of critical technologies and products in the mRNA space that enable the development and manufacturing of life-changing therapeutics, vaccines, and diagnostics, with a particular focus on nucleic acid production and biologics safety testing. We go to market with. Let me step back. We go to market with two marquee brand names or franchises, TriLink and Cygnus, that I'll touch on. The reporting segments that we have, Cygnus and TriLink, each have different growth dynamics. To kind of break that down a little bit, TriLink represents about 65% of our revenues.

Raj AsarpotaCFO

Within TriLink, there are three sub-segments, the flagship being mRNA, that consists of discovery, that's research and preclinical, GMP, and commercial revenues that will fold into the company starting in 2028 and 2029. That represents 35% of top line and expected to grow high single digits today. As you move into commercial, those revenues will add to the growth rate, making it a little bit more around like low double digits. CDMO is our contract manufacturing piece, accounting for less than 10% of revenue, growing at low double digits, and then finishing off with specialty chemistry. That's oligo synthesis consumables, just over 20%, representing low single digits. Really, TriLink is pretty diversified, but a lot of emphasis on high growth and commercial upside within mRNA. To round it off, Cygnus is 35% of revenue. This is our bioprocessing tools and analytics business.

Raj AsarpotaCFO

Cygnus is the gold standard, and it delivers steady high margins, and we have that in our model at growing at mid-single digits. When you think about mRNA drug development, TriLink as a company, we participate in every stage. Notwithstanding the spies are us, like bad press on NVIDIA, I think it is still a good analogy. Just like NVIDIA doesn't build the AI models, but supplies the compute that every model runs on, similarly, Maravai doesn't develop the drug, but we supply the leading technologies and services that hundreds of mRNA and genetic medicine programs are built on.

Raj AsarpotaCFO

As you look at these phases of drug development, from basic research to preclinical, clinical, and commercial, on the basic research side, that is where we seed the market and the start of new programs by supplying research-grade CleanCap, ModTail, oligos, et cetera, which then kind of scale up in preclinical, where we are also selling CleanCap, ModTail, and enzymes. Then once you move into clinical, that is where the GMP volume and price step-up is pretty significant. If you look at our customer base today, we have 50 GMP customers, and each of those customers have two to three programs in the works, so you can get an idea on the shots at goal we have.

Raj AsarpotaCFO

As those programs kind of progress through the clinic into commercial, once they get into the commercial space, you are now looking at five different modalities that I will talk about, but they range in terms of value from $5 million for a prophylactic vaccine to over $50 million for other modalities per program per year. So, a little bit on the phase advancement and how that factors into our revenue per program. If you think about preclinical, and then once programs get into the clinic, we probably weight every phase in our long-range plan to include modality risk, because not every program is going to succeed. As you look at this slide, when a program is in the preclinical stage, the estimated chances of reaching the market are pretty small.

Raj AsarpotaCFO

But then as you walk through the different phases in the clinic, at phase I, we have a 10% chance. Phase I to II, that goes to 12%. By the time a program is in phase III, there is a 60% chance that it hits the market. So we take all of that into account, and you can see as you move from phase I to phase III and when it gets to market, our share of consumables increases in terms of revenue performance. Then, this is the money page in terms of how we think about modalities that will provide the commercial upside that I spoke of for 2028 and 2029.

Raj AsarpotaCFO

These five modalities, the formula here is you look at the number of patients that would receive treatment per year, times the number of doses administered per year, and the mRNA within mRNA per dose to get to a price realization that delivers the expected value per program. For a prophylactic vaccine, the patients per year, that is pretty high, but the doses per year is low, similar to what a COVID vaccine would be. Also the mRNA per dose on the low side. The price realization here, given that it is more batch sizes and large scale, the expected value of that program is pretty low. But then when you advance to personalized medicine and cancer vaccines and mRNA therapeutics, here, the amount of doses increases significantly. Think about a prophylactic vaccine, maybe 35 to 50 micrograms.

Raj AsarpotaCFO

You are now with a cancer vaccine stepping up to one milligram that is administered nine, 10 times, so it grows significantly larger. For an mRNA therapeutic, it is even 15 times higher. So when you apply that into the algorithm to think about the price realization and the amount of mRNA per dose, these offer significantly higher value in terms of commercial realization. Again, the takeaway here is $5 million for a vaccine to $50 million per program per year for the other modalities once they get to peak. Then the mix of our pipeline. The current clinical program mix by phase, we have about 40% programs are in phase I, 40% in phases I, II, and then 20% in phase II and phase III. Again, 50 GMP customers in 2026, averaging two to three programs.

Raj AsarpotaCFO

Majority of our clinical pipeline is on the higher modalities that I showed versus the prophylactic vaccine example. Then I will just finish off by saying, programs in the clinical today use CleanCap, and then the programs that enter the clinic now will not only incorporate CleanCap and GMP enzymes, but also our new ModTail program, so it has a significant ramp-up in terms of the value for programs that are on the come. With that, I will now if we can get into some Q&A.

Matt StantonEquity Research Analyst

All right, perfect. That is very helpful. Appreciate that. Maybe just to kick off, being helpful to get the state of a union across kind of biopharma market. You had a good Q3, raised numbers, talked about, I think, pretty broad-based demand trends you are seeing. Would love to just kind of unpack, are you starting to see some of the funding we have seen the last few quarters translate into spend at the earlier biotechs? Then also just the large pharma side, how are they kind of thinking about mRNA today and kind of the demand across the various customer bases within biopharma?

Raj AsarpotaCFO

Yeah. Great question. Demand, as we see it, is kind of broad-based and improving quite a bit. In the third quarter, we grew our revenue enterprise by 10%, but mRNA itself grew 28%, and Cygnus had 8% growth. I think on all of those metrics, we significantly have been performing well. If you look at our discovery business in particular, that grew 27% after Q1 growth of 5%, kind of ramping up to 15%, and then eventually 27% in the third quarter after declining 20% in the year before. We think all the COVID destocking is kind of in the rearview mirror right now, and biopharma's advancing programs, and we are seeing that kind of translate into our GMP results quite nicely.

Raj AsarpotaCFO

Customers are coming back to us, one, because we have ModTail, but beyond that, if you look at the full breadth of products now on IVT kits, GMP enzymes, NTPs, it's like a full suite of products, and we are completely seeing that happen. I would say the other factor that's driving a lot of the growth in discovery is the whole mRNAbuilder. As customers come to us for these mRNA construct approaches and they can design what they want, we can provide that, and again, that's been a nice growth driver.

Matt StantonEquity Research Analyst

Okay. Maybe as we think about just the durability of those demand drivers, right, like you said, mRNA or GMP consumables, very healthy demand. You have a number of new products, ModTail being the big one, but now there's a number that are kind of seeing nice adoption. How do we think about durability, visibility of these as we think about growth into 2027? Then maybe just a finer point on the GMP COVID-related CleanCap, what that number was this year, and then will that be in the guide, or are you going to kind of level set it Yeah and kind of orient to the base business?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day